MedTrace Logo

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

NCT00624312 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-08-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of a two-dose regimen of Procrit prior to a major surgical oncology operation.

Conditions

Interventions

DRUG

Procrit

10 days prior to surgery - injection of 60,000 IU of Procrit Day of surgery - injection of 60,000 IU of Procrit

DRUG

Placebo

10 days prior to surgery - injection with 60,000 IU of placebo Day of surgery - injection with 60,000 IU of placebo

Sponsors & Collaborators

  • Ortho Biotech, Inc.

    collaborator INDUSTRY

  • University of Louisville

    lead OTHER

Principal Investigators

  • Robert Martin, MD · University of Louisville

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00624312 on ClinicalTrials.gov